Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes
- PMID: 33778971
- DOI: 10.1111/epi.16892
Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes
Abstract
Objective: To study the association between timing and characteristics of the first electroencephalography (EEG) with epileptiform discharges (ED-EEG) and epilepsy and neurodevelopment at 24 months in infants with tuberous sclerosis complex (TSC).
Methods: Patients enrolled in the prospective Epileptogenesis in a genetic model of epilepsy - Tuberous sclerosis complex (EPISTOP) trial, had serial EEG monitoring until the age of 24 months. The timing and characteristics of the first ED-EEG were studied in relation to clinical outcome. Epilepsy-related outcomes were analyzed separately in a conventionally followed group (initiation of vigabatrin after seizure onset) and a preventive group (initiation of vigabatrin before seizures, but after appearance of interictal epileptiform discharges [IEDs]).
Results: Eighty-three infants with TSC were enrolled at a median age of 28 days (interquartile range [IQR] 14-54). Seventy-nine of 83 patients (95%) developed epileptiform discharges at a median age of 77 days (IQR 23-111). Patients with a pathogenic TSC2 variant were significantly younger (P-value .009) at first ED-EEG and more frequently had multifocal IED (P-value .042) than patients with a pathogenic TSC1 variant. A younger age at first ED-EEG was significantly associated with lower cognitive (P-value .010), language (P-value .001), and motor (P-value .013) developmental quotients at 24 months. In the conventional group, 48 of 60 developed seizures. In this group, the presence of focal slowing on the first ED-EEG was predictive of earlier seizure onset (P-value .030). Earlier recording of epileptiform discharges (P-value .019), especially when multifocal (P-value .026) was associated with higher risk of drug-resistant epilepsy. In the preventive group, timing, distribution of IED, or focal slowing, was not associated with the epilepsy outcomes. However, when multifocal IEDs were present on the first ED-EEG, preventive treatment delayed the onset of seizures significantly (P-value <.001).
Significance: Early EEG findings help to identify TSC infants at risk of severe epilepsy and neurodevelopmental delay and those who may benefit from preventive treatment with vigabatrin.
Keywords: EEG; epilepsy; epileptogenesis; neurodevelopment; tuberous sclerosis complex.
© 2021 International League Against Epilepsy.
Similar articles
-
Electro-clinical and neurodevelopmental outcome in six children with early diagnosis of tuberous sclerosis complex and role of the genetic background.Ital J Pediatr. 2020 Mar 27;46(1):36. doi: 10.1186/s13052-020-0801-0. Ital J Pediatr. 2020. PMID: 32216820 Free PMC article.
-
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.Ann Neurol. 2021 Feb;89(2):304-314. doi: 10.1002/ana.25956. Epub 2020 Nov 27. Ann Neurol. 2021. PMID: 33180985 Free PMC article. Clinical Trial.
-
Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study.Epilepsia. 2019 Dec;60(12):2428-2436. doi: 10.1111/epi.16379. Epub 2019 Nov 5. Epilepsia. 2019. PMID: 31691264 Free PMC article.
-
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.Eur J Paediatr Neurol. 2018 Sep;22(5):738-748. doi: 10.1016/j.ejpn.2018.05.006. Epub 2018 May 24. Eur J Paediatr Neurol. 2018. PMID: 29880258 Review.
-
Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis.Arch Pediatr. 2022 Dec;29(5S):5S8-5S13. doi: 10.1016/S0929-693X(22)00284-6. Arch Pediatr. 2022. PMID: 36585069 Review.
Cited by
-
Children with Autism Spectrum Disorder and Abnormalities of Clinical EEG: A Qualitative Review.J Clin Med. 2024 Jan 3;13(1):279. doi: 10.3390/jcm13010279. J Clin Med. 2024. PMID: 38202286 Free PMC article. Review.
-
Risk Factors Associated with Refractory Epilepsy in Patients with Tuberous Sclerosis Complex: A Systematic Review.J Clin Med. 2021 Nov 24;10(23):5495. doi: 10.3390/jcm10235495. J Clin Med. 2021. PMID: 34884198 Free PMC article. Review.
-
Methodological insights from the EPISTOP trial to designing clinical trials in rare diseases-A secondary analysis of a randomized clinical trial.PLoS One. 2024 Dec 3;19(12):e0312936. doi: 10.1371/journal.pone.0312936. eCollection 2024. PLoS One. 2024. PMID: 39625912 Free PMC article. Clinical Trial.
-
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.CNS Drugs. 2021 Sep;35(9):965-983. doi: 10.1007/s40263-021-00835-8. Epub 2021 Aug 21. CNS Drugs. 2021. PMID: 34417984 Review.
-
Recognizing Pediatric Tuberous Sclerosis Complex Based on Multi-Contrast MRI and Deep Weighted Fusion Network.Bioengineering (Basel). 2023 Jul 22;10(7):870. doi: 10.3390/bioengineering10070870. Bioengineering (Basel). 2023. PMID: 37508897 Free PMC article.
References
REFERENCES
-
- Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.
-
- Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14:733-45.
-
- Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51:1236-41.
-
- Capal JK, Bernardino-Cuesta B, Horn PS, Murray D, Byars AW, Bing NM, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70:245-52.
-
- Jeong A, Nakagawa JA, Wong M. Predictors of drug-resistant epilepsy in tuberous sclerosis complex. J Child Neurol. 2017;32:1092-8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical